Opendata, web and dolomites

THERAPROBES SIGNED

Biodegradable fluorescent nanoprobes for early detection of (pre)malignant lesions of the gastrointestinal tract

Total Cost €

0

EC-Contrib. €

0

Partnership

0

Views

0

 THERAPROBES project word cloud

Explore the words cloud of the THERAPROBES project. It provides you a very rough idea of what is the project "THERAPROBES" about.

miss    critical    diagnosing    tumor    improves    variability    inter    ubiquitously    misses    gastrointestinal    endoscopic    directing    quality    sites    rate    near    outcomes    50    accurately    detect    white    specificity    sampling    visualization    80    accuracy    progress    subtle    patients    size    sensitivity    detected    imaging    ablation    33    regular    poor    nanoprobes    clinically    strategy    biodegradable    symptomatic    tract    delineation    survival    active    treatments    malignant    impacting    aggressive    intervention    gitract    reliably    requiring    sensitive    marker    true    therapeutic    asymptomatic    unmet    surveillance    amenable    lack    25    augmented    treatment    successful    tremendous    vascular    curative    disease    resection    systemic    compromises    negatively    diagnostic    permeability    inherent    errors    clinical    gi    rates    diagnosis    decrease    silica    fsn    lesions    agents    operator    optical    fluorescent    patient    paradigm    contrast    accurate    risk    biopsy    solely    life    detection    appearance    minus    random    physician    accumulate    applicable    routine    scales    progression    light    endoscopy    chance    recur    fsns    site    lesion    time   

Project "THERAPROBES" data sheet

The following table provides information about the project.

Coordinator
PERCUROS BV 

Organization address
address: PLESMANLAAN 1
city: LEIDEN
postcode: 2333 BZ
website: www.percuros.com

contact info
title: n.a.
name: n.a.
surname: n.a.
function: n.a.
email: n.a.
telephone: n.a.
fax: n.a.

 Coordinator Country Netherlands [NL]
 Total cost 187˙572 €
 EC max contribution 187˙572 € (100%)
 Programme 1. H2020-EU.1.3.2. (Nurturing excellence by means of cross-border and cross-sector mobility)
 Code Call H2020-MSCA-IF-2018
 Funding Scheme MSCA-IF-EF-SE
 Starting year 2019
 Duration (year-month-day) from 2019-09-01   to  2021-08-31

 Partnership

Take a look of project's partnership.

# participants  country  role  EC contrib. [€] 
1    PERCUROS BV NL (LEIDEN) coordinator 187˙572.00

Map

 Project objective

Accurate diagnosis of (pre)malignant gastrointestinal (GI)-tract lesions is critical for patient survival. Early detection of asymptomatic disease of the GItract improves the chance of curative intervention by 50−80% as compared to poor five-year survival rates for symptomatic advanced malignant disease. Regular endoscopic surveillance in high-risk patients misses 25% of (pre)malignant lesions – the most clinically relevant marker for malignant progression. This clinically significant miss rate is due to the subtle appearance of such lesions under white-light endoscopy and sampling errors inherent to a random-biopsy surveillance paradigm, which increases inter-operator variability and compromises diagnostic accuracy. Even when malignant disease is detected, lack of sensitive contrast agents compromises delineation of the true extent of the lesion. These factors decrease the physician’s ability to achieve successful therapeutic intervention through resection or ablation. About 33% of GI-tract lesions progress or recur at or near the therapeutic site, commonly requiring aggressive yet often non-curative, systemic treatments negatively impacting the patients’ quality of life. There is an unmet clinical need for endoscopic optical imaging approaches that reliably detect those lesions with high sensitivity and specificity. To develop a clinically viable strategy, I propose to use biodegradable, fluorescent silica nanoprobes (FSN) that provide real-time visualization of the lesions over a range of scales during routine endoscopy. Since FSNs accumulate at the tumor sites solely due to their size and increased vascular permeability, no active targeting is needed, making these imaging agents ubiquitously applicable. Endoscopy augmented with FSNs has tremendous potential for better outcomes particularly in high-risk patients by accurately diagnosing and directing treatment specifically to early lesions at a time when patients are amenable to curative therapeutic intervention.

Are you the coordinator (or a participant) of this project? Plaese send me more information about the "THERAPROBES" project.

For instance: the website url (it has not provided by EU-opendata yet), the logo, a more detailed description of the project (in plain text as a rtf file or a word file), some pictures (as picture files, not embedded into any word file), twitter account, linkedin page, etc.

Send me an  email (fabio@fabiodisconzi.com) and I put them in your project's page as son as possible.

Thanks. And then put a link of this page into your project's website.

The information about "THERAPROBES" are provided by the European Opendata Portal: CORDIS opendata.

More projects from the same programme (H2020-EU.1.3.2.)

EVOMET (2019)

The rise and fall of metastatic clones under immune attack

Read More  

TCFLAND2SEA (2020)

Thawing Carbon From LAND to SEA: Microbial Degradation of Organic Matter and Response to Thawing Permafrost in the Northeast Siberian Land-Shelf System

Read More  

AsymmFlow (2020)

Go with the continuous flow: Asymmetric Synthesis of Bioactive Alkaloids by Multistep Continuous-Flow Processes

Read More